“Gary has served as Mesa’s CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the company’s foundation, and the implementation of The ...
The authors conclude that mRNA vaccines “induce a gene-altering [mode of action], reprogramming host expression programs” that go far beyond inflammatory responses to Spike protein. Effects include ...
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 ...
Schlafly concludes that hospitals are often hostile to respecting the right to free exercise of religion with respect to vaccination exemption. Requests must be carefully formulated, and litigation as ...
A 2026 informational consumer research report examining portable nebulizer technology, vibrating mesh atomization systems, respiratory comfort features, pricing transparency, and verification ...
According to the product labeling, Slim Force is manufactured in an FDA-registered facility in the United States. The label identifies the product as GMO-free and assembled in the USA. Each bottle ...
Novonesis ranked 6th on the list of Great Employers to Work for in North Carolina. With more than 700 employees across North Carolina, Novonesis’ recognition reflects its commitment to building a ...
Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. “We are pleased with our ...
As life sciences research continues to expand worldwide, Cytek’s Singapore operations stand as a critical global component of its regional manufacturing strategy, advancing scientific discovery and ...
Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension (rHTN). Additionally, untreated moderate-to-severe OSA increases ...
Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well tolerated BERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix ...
The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results